Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

Immunocompromised: full-pipeline trial registry

2 of 3 indexed Immunocompromised trials are currently recruiting.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Immunocompromised: 3 US clinical trials tracked, 2 recruiting.

Immunocompromised is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Karius, running 1 of these trials.

Enrollment posture brief

Registry condition immunocompromised

OPEN 2 | RECR 67% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Immunocompromised (this)67%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Immunocompromised

Immunocompromised lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Immunocompromised on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Immunocompromised is recruiting above its size-band peers.

    2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 31

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Immunocompromised records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

DAS181 OL Drug
1 trials
DAS181 Covid-19 Drug
1 trials
DAS181 Drug
1 trials
Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes Biological
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Immunocompromised trials. A trial with sites in several states counts in each.

Illinois 2 trials
Texas 1 trials
Missouri 1 trials
Minnesota 1 trials
Michigan 1 trials
Maryland 1 trials
Massachusetts 1 trials
Louisiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Immunocompromised page

3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Immunocompromised trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Karius sponsors the most Immunocompromised trials on record, review their full trial history before evaluating a specific study. See Karius's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Immunocompromised condition card totals 3 registered trials; most-linked intervention DAS181 OL; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.